Novo Nordisk : Le marché du GLP-1 se porte bien
>Une croissance de 38% en topline et de 47% de son EBIT lors du T3 - Novo Nordisk avait pré-publié mi-octobre à la fois sa croissance du T3 ainsi qu’une révision à la hausse de sa guidance 2023. Les ventes globales du groupe ressortent ainsi à 58.731 MdDKK en croissance de 38% à tcc (29% / 33% à tcc sur les 9M). Cette performance est largement tirée par les ventes en volume de sa franchise GLP-1 et tout particulièrement Ozempic aux Etats-Unis même si celui-ci re...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.